eHealth (EHTH) 10-Q 8 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 03, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-33071
Entity Registrant Name	EHEALTH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	56-2357876
Entity Address, Address Line One	2625 AUGUSTINE DRIVE, SUITE 150
Entity Address, City or Town	SANTA CLARA
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054
City Area Code	650
Local Phone Number	210-3150
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	EHTH
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		28,364,821
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Central Index Key	0001333493
Current Fiscal Year End Date	--12-31

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 152,118	$ 144,401
Short-term marketable securities	8,469	0
Accounts receivable	522	2,633
Contract assets – commissions receivable – current	212,399	242,749
Prepaid expenses and other current assets	23,233	11,301
Total current assets	396,741	401,084
Contract assets – commissions receivable – non-current	568,177	641,555
Property and equipment, net	5,427	5,501
Operating lease right-of-use assets	23,943	26,516
Restricted cash	3,090	3,239
Other assets	28,998	34,716
Total assets	1,026,376	1,112,611
Current liabilities:
Accounts payable	7,004	6,732
Accrued compensation and benefits	26,793	20,690
Accrued marketing expenses	7,423	23,770
Lease liabilities – current	6,902	6,486
Other current liabilities	5,126	2,887
Total current liabilities	53,248	60,565
Long-term debt	67,321	66,129
Deferred income taxes – non-current	23,048	32,359
Lease liabilities – non-current	30,138	34,187
Other non-current liabilities	4,101	5,132
Total liabilities	177,856	198,372
Commitments and contingencies (Note 8)
Convertible preferred stock	288,883	263,284
Stockholders’ equity:
Common stock	40	40
Additional paid-in capital	794,135	777,187
Treasury stock, at cost	(199,998)	(199,998)
Retained earnings (accumulated deficit)	(34,407)	73,799
Accumulated other comprehensive loss	(133)	(73)
Total stockholders’ equity	559,637	650,955
Total liabilities, convertible preferred stock and stockholders’ equity	$ 1,026,376	$ 1,112,611

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 64,718	$ 53,376	$ 205,209	$ 209,035
Operating costs and expenses:
Cost of revenue	194	494	662	790
Marketing and advertising	28,988	30,556	85,171	118,973
Customer care and enrollment	40,682	29,398	100,501	100,711
Technology and content	13,828	19,399	43,872	56,842
General and administrative	20,422	17,300	63,445	54,485
Impairment, restructuring and other charges	0	4,498	0	10,690
Total operating costs and expenses	104,114	101,645	293,651	342,491
Loss from operations	(39,396)	(48,269)	(88,442)	(133,456)
Other expense, net	(138)	(647)	(622)	(2,835)
Loss before income taxes	(39,534)	(48,916)	(89,064)	(136,291)
Benefit from income taxes	(2,509)	(9,767)	(8,660)	(26,898)
Net loss	(37,025)	(39,149)	(80,404)	(109,393)
Preferred stock dividends	(5,320)	(4,933)	(15,644)	(14,420)
Change in preferred stock redemption value	(4,898)	(2,916)	(12,158)	(8,173)
Net loss attributable to common stockholders	$ (47,243)	$ (46,998)	$ (108,206)	$ (131,986)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (1.68)	$ (1.72)	$ (3.88)	$ (4.83)
Diluted (in dollars per share)	$ (1.68)	$ (1.72)	$ (3.88)	$ (4.83)
Weighted-average number of shares used in per share amounts:
Basic (in shares)	28,114	27,346	27,863	27,329
Diluted (in shares)	28,114	27,346	27,863	27,329
Comprehensive income (loss):
Net loss	$ (37,025)	$ (39,149)	$ (80,404)	$ (109,393)
Unrealized gain (loss) for available-for-sale debt securities, net of tax	(15)	(4)	5	(6)
Foreign currency translation adjustments	73	(245)	(65)	(483)
Comprehensive loss	(36,967)	(39,398)	(80,464)	(109,882)
Commission
Revenue:
Total revenue	57,239	48,977	185,428	190,662
Other
Revenue:
Total revenue	$ 7,479	$ 4,399	$ 19,781	$ 18,373

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Dec. 31, 2021		38,704
Beginning balance at Dec. 31, 2021	$ 749,519	$ 39	$ 755,875	$ (199,998)	$ 193,213	$ 390
Beginning balance (in shares) at Dec. 31, 2021				12,016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		176
Issuance of common stock in connection with equity incentive plans	1,054		1,054
Repurchase of shares to satisfy employee tax withholding obligations	(508)		(508)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				37
Dividends and accretion related to convertible preferred stock	(7,218)				(7,218)
Stock-based compensation	5,791		5,791
Other comprehensive income (loss), net of tax	31					31
Net loss	(32,742)				(32,742)
Ending balance (in shares) at Mar. 31, 2022		38,880
Ending balance at Mar. 31, 2022	715,927	$ 39	762,212	$ (199,998)	153,253	421
Ending balance (in shares) at Mar. 31, 2022				12,053
Beginning balance (in shares) at Dec. 31, 2021		38,704
Beginning balance at Dec. 31, 2021	749,519	$ 39	755,875	$ (199,998)	193,213	390
Beginning balance (in shares) at Dec. 31, 2021				12,016
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(109,393)
Ending balance (in shares) at Sep. 30, 2022		39,707
Ending balance at Sep. 30, 2022	$ 633,498	$ 40	772,328	$ (199,998)	61,227	(99)
Ending balance (in shares) at Sep. 30, 2022	12,400			12,358
Beginning balance (in shares) at Mar. 31, 2022		38,880
Beginning balance at Mar. 31, 2022	$ 715,927	$ 39	762,212	$ (199,998)	153,253	421
Beginning balance (in shares) at Mar. 31, 2022				12,053
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		530
Issuance of common stock in connection with equity incentive plans	1	$ 1
Repurchase of shares to satisfy employee tax withholding obligations	(1,926)		(1,926)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				234
Dividends and accretion related to convertible preferred stock	(7,526)				(7,526)
Issuance of common stock for employee stock purchase program (in shares)		83
Issuance of common stock for employee stock purchase program	873		873
Stock-based compensation	6,005		6,005
Other comprehensive income (loss), net of tax	(271)					(271)
Net loss	(37,502)				(37,502)
Ending balance (in shares) at Jun. 30, 2022		39,493
Ending balance at Jun. 30, 2022	675,581	$ 40	767,164	$ (199,998)	108,225	150
Ending balance (in shares) at Jun. 30, 2022				12,287
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		214
Repurchase of shares to satisfy employee tax withholding obligations	(467)		(467)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				71
Dividends and accretion related to convertible preferred stock	(7,849)				(7,849)
Stock-based compensation	5,631		5,631
Other comprehensive income (loss), net of tax	(249)					(249)
Net loss	(39,149)				(39,149)
Ending balance (in shares) at Sep. 30, 2022		39,707
Ending balance at Sep. 30, 2022	$ 633,498	$ 40	772,328	$ (199,998)	61,227	(99)
Ending balance (in shares) at Sep. 30, 2022	12,400			12,358
Beginning balance (in shares) at Dec. 31, 2022		39,977
Beginning balance at Dec. 31, 2022	$ 650,955	$ 40	777,187	$ (199,998)	73,799	(73)
Beginning balance (in shares) at Dec. 31, 2022				12,415
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		160
Repurchase of shares to satisfy employee tax withholding obligations	(428)		(428)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				57
Dividends and accretion related to convertible preferred stock	(8,170)				(8,170)
Stock-based compensation	5,306		5,306
Other comprehensive income (loss), net of tax	123					123
Net loss	(19,878)				(19,878)
Ending balance (in shares) at Mar. 31, 2023		40,137
Ending balance at Mar. 31, 2023	627,908	$ 40	782,065	$ (199,998)	45,751	50
Ending balance (in shares) at Mar. 31, 2023				12,472
Beginning balance (in shares) at Dec. 31, 2022		39,977
Beginning balance at Dec. 31, 2022	650,955	$ 40	777,187	$ (199,998)	73,799	(73)
Beginning balance (in shares) at Dec. 31, 2022				12,415
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(80,404)
Ending balance (in shares) at Sep. 30, 2023		40,876
Ending balance at Sep. 30, 2023	$ 559,637	$ 40	794,135	$ (199,998)	(34,407)	(133)
Ending balance (in shares) at Sep. 30, 2023	12,700			12,658
Beginning balance (in shares) at Mar. 31, 2023		40,137
Beginning balance at Mar. 31, 2023	$ 627,908	$ 40	782,065	$ (199,998)	45,751	50
Beginning balance (in shares) at Mar. 31, 2023				12,472
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		320
Repurchase of shares to satisfy employee tax withholding obligations	(623)		(623)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				70
Dividends and accretion related to convertible preferred stock	(9,414)				(9,414)
Issuance of common stock for employee stock purchase program (in shares)		76
Issuance of common stock for employee stock purchase program	262		262
Stock-based compensation	6,518		6,518
Other comprehensive income (loss), net of tax	(241)					(241)
Net loss	(23,501)				(23,501)
Ending balance (in shares) at Jun. 30, 2023		40,533
Ending balance at Jun. 30, 2023	600,909	$ 40	788,222	$ (199,998)	12,836	(191)
Ending balance (in shares) at Jun. 30, 2023				12,542
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with equity incentive plans (in shares)		343
Repurchase of shares to satisfy employee tax withholding obligations	(884)		(884)
Repurchase of shares to satisfy employee tax withholding obligations (in shares)				116
Dividends and accretion related to convertible preferred stock	(10,218)				(10,218)
Stock-based compensation	6,797		6,797
Other comprehensive income (loss), net of tax	58					58
Net loss	(37,025)				(37,025)
Ending balance (in shares) at Sep. 30, 2023		40,876
Ending balance at Sep. 30, 2023	$ 559,637	$ 40	$ 794,135	$ (199,998)	$ (34,407)	$ (133)
Ending balance (in shares) at Sep. 30, 2023	12,700			12,658

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating activities:
Net loss	$ (80,404)	$ (109,393)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	1,908	2,971
Amortization of internally developed software	13,233	12,714
Stock-based compensation expense	17,741	15,934
Deferred income taxes	(9,311)	(27,207)
Impairment charges	0	3,734
Other non-cash items	5	1,333
Changes in operating assets and liabilities:
Accounts receivable	2,110	3,946
Contract assets – commissions receivable	104,160	122,410
Prepaid expenses and other assets	(12,597)	2,728
Accounts payable	181	(7,118)
Accrued compensation and benefits	6,102	(1,345)
Accrued marketing expenses	(16,347)	(28,175)
Deferred revenue	1,323	(284)
Accrued expenses and other liabilities	(1,410)	(538)
Net cash provided by (used in) operating activities	26,694	(8,290)
Investing activities:
Capitalized internal-use software and website development costs	(7,028)	(12,540)
Purchases of property and equipment and other assets	(1,759)	(192)
Purchases of marketable securities	(48,602)	(8,402)
Proceeds from redemption and maturities of marketable securities	40,900	45,269
Net cash provided by (used in) investing activities	(16,489)	24,135
Financing activities:
Net proceeds from debt financing	0	64,862
Net proceeds from exercise of common stock options and employee stock purchases	262	1,054
Repurchase of shares to satisfy employee tax withholding obligations	(1,935)	(2,901)
Principal payments in connection with leases	(33)	(90)
Payments of preferred stock dividends	(873)	0
Net cash provided by (used in) financing activities	(2,579)	62,925
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(58)	(438)
Net increase in cash, cash equivalents and restricted cash	7,568	78,332
Cash, cash equivalents and restricted cash at beginning of period	147,640	85,165
Cash, cash equivalents and restricted cash at end of period	$ 155,208	$ 163,497

Summary of Business and Signifi

Summary of Business and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Business and Significant Accounting Policies	Summary of Business and Significant Accounting Policies Description of Business – eHealth, Inc., a Delaware corporation, and its consolidated subsidiaries (collectively, “eHealth”) is a leading private online health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to expertly guide consumers through their health insurance enrollment and related options, when, where and how they prefer. Our platform leverages technology to solve a critical problem in a large and growing market by aiding consumers in what has traditionally been a complex, confusing and opaque health insurance purchasing process. Our omnichannel consumer engagement platform differentiates our offering from other brokers and enables consumers to use our services online, by telephone with a licensed insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities. We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide. Our plan recommendation tool curates this broad plan selection by analyzing customer health-related information against plan data for insurance coverage fit. This tool is supported by a unified data platform and is available to our ecommerce customers and our benefit advisors. We strive to be the most trusted partner to the consumer in their life’s journey through the health insurance market. Unless otherwise specified or required by the context, references in this Quarterly Report on Form 10-Q to “eHealth,” “the Company,” “we,” “us” or “our” mean eHealth, Inc. and its consolidated direct and indirect wholly-owned subsidiaries. Basis of Presentation – The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023 and other condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022 are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2022 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on March 1, 2023. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2022 and include all adjustments necessary for the fair presentation of our financial position as of September 30, 2023 and December 31, 2022, and our results of operations for the periods presented. The results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2023 and therefore, should not be relied upon as an indicator of future results. Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the fair value of investments, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates. There have been no material changes for the nine months ended September 30, 2023 to our significant accounting policies discussed in our Annual Report on Form 10-K for the year ended December 31, 2022. Recently Adopted Accounting Pronouncements We did not adopt any new accounting pronouncements during the nine months ended September 30, 2023.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	Revenue Disaggregation of Revenue – The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Medicare Medicare Advantage $ 43,721 $ 37,454 $ 143,231 $ 152,061 Medicare Supplement 2,630 2,534 7,786 11,291 Medicare Part D 2,046 1,167 4,686 2,165 Total Medicare 48,397 41,155 155,703 165,517 Individual and Family (1) Non-Qualified Health Plans 1,560 1,991 6,904 5,970 Qualified Health Plans 681 714 4,084 2,975 Total Individual and Family 2,241 2,705 10,988 8,945 Ancillary Short-term 870 967 2,426 3,287 Dental 649 715 2,317 2,249 Vision 486 245 972 741 Other 555 674 1,788 1,803 Total Ancillary 2,560 2,601 7,503 8,080 Small Business 3,884 2,640 12,557 8,546 Commission Bonus and Other 157 (124) (1,323) (426) Total Commission Revenue 57,239 48,977 185,428 190,662 Other Revenue Sponsorship and Advertising Revenue 7,135 3,805 18,195 16,540 Other 344 594 1,586 1,833 Total Other Revenue 7,479 4,399 19,781 18,373 Total Revenue $ 64,718 $ 53,376 $ 205,209 $ 209,035 _____________ (1) We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related, small business or ancillary plans. Individual and family plans include both qualified and non-qualified plans. Qualified health plans meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans do not meet the requirements of the Affordable Care Act and are not offered through the government-run health insurance exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Medicare Commission revenue from members approved during the period $ 39,169 $ 39,652 $ 131,792 $ 173,790 Net commission revenue from members approved in prior periods (1) 9,291 1,685 22,746 (9,052) Total Medicare segment commission revenue $ 48,460 $ 41,337 $ 154,538 $ 164,738 Individual, Family and Small Business Commission revenue from members approved during the period $ 3,829 $ 3,600 $ 13,835 $ 14,254 Commission revenue from renewals of small business members during the period 2,028 2,200 7,299 7,281 Net commission revenue from members approved in prior periods (1) 2,922 1,840 9,756 4,389 Total Individual, Family and Small Business segment commission revenue $ 8,779 $ 7,640 $ 30,890 $ 25,924 Total commission revenue from members approved during the period $ 42,998 $ 43,252 $ 145,627 $ 188,044 Commission revenue from renewals of small business members during the period 2,028 2,200 7,299 7,281 Total net commission revenue from members approved in prior periods (1)(2) 12,213 3,525 32,502 (4,663) Total commission revenue $ 57,239 $ 48,977 $ 185,428 $ 190,662 _____________ (1) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (2) The impacts of total net commission revenue from members approved in prior periods were $0.43 and $0.13 per basic and diluted share for the three months ended September 30, 2023 and 2022, respectively. The impacts of total net commission revenue from members approved in prior periods were $1.17 and $(0.17) per basic and diluted share for the nine months ended September 30, 2023 and 2022, respectively. The total reductions to revenue from members approved in prior periods were $0.8 million and $2.1 million for the three months ended September 30, 2023 and 2022, respectively, and $3.7 million and $15.8 million for the nine months ended September 30, 2023 and 2022, respectively. These reductions to revenue primarily relate to the Medicare segment.

Supplemental Financial Statemen

Supplemental Financial Statement Information	9 Months Ended
	Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Supplemental Financial Statement Information	Supplemental Financial Statement Information Cash, Cash Equivalents and Restricted Cash We consider all investments with an original maturity of 90 days or less from the date of purchase to be cash equivalents. Cash and cash equivalents are stated at fair value. We also invest in marketable securities that are measured and recorded at fair value. See Note 4 – Fair Value Measurements for further discussion about our marketable securities. Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): September 30, 2023 December 31, 2022 Cash $ 22,835 $ 17,776 Cash equivalents 129,283 126,625 Cash and cash equivalents 152,118 144,401 Restricted cash 3,090 3,239 Total cash, cash equivalents and restricted cash $ 155,208 $ 147,640 As of September 30, 2023 and December 31, 2022, we had $3.1 million and $3.2 million of restricted cash which was classified as a non-current asset on our Condensed Consolidated Balance Sheets. This amount collateralizes letters of credit related to certain lease commitments. Contract Assets and Accounts Receivable We estimate an allowance for credit losses using relevant available information from internal and external sources, related to past events, current conditions and reasonable and supportable forecasts. Specifically, for the purpose of measuring the probability of default parameters, we utilize Capital IQ’s, Standard & Poor’s and Moody’s analytics. Our estimates of loss given default are determined by using our historical collections data as well as historical information obtained through our research and review of other insurance related companies. Our estimated exposure at default is determined by applying these internal and external data sources to our commissions receivable balances. As such, we apply an immediate reversion method and revert to historical loss information when computing our credit loss exposure. Credit loss expenses are assessed quarterly and are included in the “General and administrative” line in our Condensed Consolidated Statements of Comprehensive Loss. There were no write-offs during the nine months ended September 30, 2023 or for the year ended December 31, 2022. The change in the allowance for credit losses is summarized as follows (in thousands): September 30, 2023 December 31, 2022 Beginning balance $ 2,398 $ 2,198 Change in allowance (433) 200 Ending balance $ 1,965 $ 2,398 Our contract assets – commissions receivable activities, net of credit loss allowances, are summarized as follows (in thousands): Medicare Segment IFP/SMB Segment Total Beginning balance at December 31, 2022 $ 817,043 $ 67,261 $ 884,304 Commission revenue from members approved during the period 131,792 13,835 145,627 Commission revenue from renewals of small business members during the period — 7,299 7,299 Net commission revenue from members approved in prior periods 22,746 9,756 32,502 Cash receipts (258,724) (30,865) (289,589) Net change in credit loss allowance 396 37 433 Ending balance at September 30, 2023 $ 713,253 $ 67,323 $ 780,576 Credit Risk Our financial instruments that are exposed to concentrations of credit risk principally consist of cash, cash equivalents, marketable securities, contract assets – commissions receivable and accounts receivable. We invest our cash and cash equivalents with major banks and financial institutions and, at times, such investments are in excess of federally insured limits. We also have deposits with major banks in China that are denominated in both U.S. dollars and Chinese Yuan Renminbi and are not insured by the U.S. federal government. The deposits in China were $2.8 million as of September 30, 2023. See Note 4 – Fair Value Measurements for more information regarding our marketable securities. We do not require collateral or other security for either our contract assets or accounts receivable. Carriers that represented 10% or more of our total contract assets – commissions receivable and accounts receivable balances are summarized as follows: September 30, 2023 December 31, 2022 Humana 27 % 26 % UnitedHealthCare (1) 25 % 24 % Aetna (1) 15 % 16 % _____________ (1) Percentages include the carriers’ subsidiaries. Prepaid Expenses and Other Current Assets – Our prepaid expenses and other current assets are summarized as follows (in thousands): September 30, 2023 December 31, 2022 Prepaid expenses $ 12,629 $ 2,858 Prepaid software and maintenance contracts 6,304 5,211 Prepaid licenses 3,289 1,116 Prepaid insurance 775 1,893 Other current assets 236 223 Prepaid expenses and other current assets $ 23,233 $ 11,301

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements We define fair value as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques we use to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability. Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy (in thousands): September 30, 2023 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 502 $ 502 $ — $ — $ 502 Commercial paper 113,884 — 113,884 — 113,884 Agency bonds 14,897 — 14,897 — 14,897 Short-term marketable securities Commercial paper 8,469 — 8,469 — 8,469 Total assets measured at fair value $ 137,752 $ 502 $ 137,250 $ — $ 137,752 December 31, 2022 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 13,015 $ 13,015 $ — $ — $ 13,015 Commercial paper 112,268 — 112,268 — 112,268 Agency bonds 1,342 — 1,342 — 1,342 Total assets measured at fair value $ 126,625 $ 13,015 $ 113,610 $ — $ 126,625 We endeavor to utilize the best available information in measuring fair value. Our money market funds are measured at fair value based on quoted prices in active markets and are classified as Level 1 within the fair value hierarchy. Our available-for-sale marketable securities, which include commercial paper and agency bonds with maturities of less than one year, are measured at fair value using quoted market prices to the extent available or alternative pricing sources and models utilizing market observable inputs and are classified as Level 2 within the fair value hierarchy. There were no transfers between the hierarchy levels during the nine months ended September 30, 2023 or the year ended December 31, 2022. The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of September 30, 2023 As of December 31, 2022 Amortized Cost Fair Value Amortized Cost Fair Value Due in 1 year $ 137,796 $ 137,752 $ 126,664 $ 126,625 Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income (loss) and summarized as follows (in thousands): September 30, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 502 $ — $ — $ 502 Commercial paper 113,927 — (43) 113,884 Agency bonds 14,895 2 — 14,897 Short-term marketable securities Commercial paper 8,472 — (3) 8,469 Total $ 137,796 $ 2 $ (46) $ 137,752 December 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 13,015 $ — $ — $ 13,015 Commercial paper 112,307 — (39) 112,268 Agency bonds 1,342 — — 1,342 Total $ 126,664 $ — $ (39) $ 126,625 As of September 30, 2023 and December 31, 2022, we had 28

Equity

Equity	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Equity	Equity 2021 Inducement Plan – On September 22, 2021, the Company adopted an inducement plan (the “2021 Inducement Plan”), pursuant to which the Company reserved 0.4 million shares of its common stock (subject to customary adjustments in the event of a change in capital structure of the Company) to be used exclusively for grants of awards to individuals who were not previously employees or directors of the Company, other than following a bona fide period of non-employment, as an inducement material to the individual’s entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules (“Nasdaq Rules”). In March 2022 and September 2022, the Company amended and restated its 2021 Inducement Plan to reserve an additional 0.5 million and 1.5 million shares of its common stock, respectively (as amended and restated, the “A&R 2021 Inducement Plan”). The 2021 Inducement Plan and its amendments were approved by the Company’s Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Rules, and the terms and conditions of the A&R 2021 Inducement Plan and awards to be granted thereunder are substantially similar to our stockholder-approved Amended and Restated 2014 Equity Incentive Plan. As of September 30, 2023, 2.0 million shares were issued under the A&R 2021 Inducement Plan. Stock Repurchase Programs – We had no stock repurchase activity during the three and nine months ended September 30, 2023 or 2022. As of September 30, 2023 and 2022, we had a total o f 12.7 million and 12.4 million shares, respectively, held in treasury. As of September 30, 2023 and 2022, we had 2.0 million and 1.7 million shares, respectively, in treasury that were previously surrendered by employees to satisfy tax withholding due in connection with the vesting of certain restricted stock units as well as 10.7 million shares previously repurchased under our past repurchase programs. For accounting purposes, common stock repurchased under our stock repurchase programs is recorded based upon the settlement date of the applicable trade. Such repurchased shares are held in treasury and are presented using the cost method. Stock-Based Compensation Expense – Our stock-based compensation expense is summarized as follows by award types for the periods presented below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restricted stock units (1) $ 6,098 $ 4,687 $ 16,559 $ 14,625 Common stock options 333 313 899 864 Employee stock purchase program 123 144 283 445 Total stock-based compensation expense $ 6,554 $ 5,144 $ 17,741 $ 15,934 Related tax benefit recognized $ 1,543 $ 1,194 $ 4,162 $ 3,702 _________ (1) Amounts include market-based and performance-based restricted stock units. The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Marketing and advertising $ 605 $ 570 $ 1,598 $ 1,311 Customer care and enrollment 836 610 2,229 1,576 Technology and content 1,306 1,341 3,384 5,012 General and administrative 3,807 2,623 10,530 8,035 Total stock-based compensation expense $ 6,554 $ 5,144 $ 17,741 $ 15,934 Amount capitalized for internal-use software 243 487 880 1,493 Total stock-based compensation $ 6,797 $ 5,631 $ 18,621 $ 17,427

Convertible Preferred Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2023
Temporary Equity Disclosure [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock Pursuant to an investment agreement dated February 17, 2021 with Echelon Health SPV, LP (“H.I.G.”), an investment vehicle of H.I.G. Capital (the “H.I.G. Investment Agreement”), we issued and sold to H.I.G., in a private placement, 2,250,000 shares of our newly designated Series A convertible preferred stock (the “Series A Preferred Stock”), par value $0.001 per share, at an aggregate purchase price of $225.0 million on April 30, 2021 (the “Closing Date”). We received $214.0 million in net proceeds from the private placement with H.I.G., net of sales commissions and certain transaction fees totaling $11.0 million. The Series A Preferred Stock ranks senior to all other equity securities of the Company with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Dividends – Dividends initially accrued on the Series A Preferred Stock daily at 8% per annum on the stated value of $100 per share (the “Stated Value”), and were payable in kind (“PIK”) beginning on June 30, 2021 through the second anniversary of the Closing Date. Subsequent to the second anniversary of the Closing Date, dividends continue to accrue at 8% per annum, with 6% PIK and 2% payable in cash in arrears beginning on June 30, 2023. Dividends compound semiannually and are PIK and payable in cash in arrears, as applicable, on June 30 and December 31 of each year (each a “Dividend Payment Date”). PIK dividends are cumulative and are added to the Accrued Value (as defined below). “Accrued Value” means, as of any date, with respect to any share of Series A Preferred Stock, the sum of the Stated Value per share plus, on each Dividend Payment Date, on a cumulative basis, all PIK dividends that have accrued on such share but that have not previously been added to the Accrued Value. During the second quarter of 2023, we made the initial cash dividend payment in the aggregate amount of $0.9 million and as of September 30, 2023, w e have accrued $1.3 million for cash dividends. T he Series A Preferred Stock participates, on an as-converted basis, in all dividends paid to the holders of our common stock. Conversion Rights – The Series A Preferred Stock is convertible at any time into common stock at a conversion rate equal to (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the conversion price as of the applicable conversion date (the “Conversion Price”). As of the date of this report, the Conversion Price is equal to $79.5861 per share. This Conversion Price is subject to further adjustment and the number of shares of common stock issuable upon conversion of the Series A Preferred Stock is subject to certain limitations, each as set forth in the Certificate of Designations of Series A Preferred Stock, as filed with the Secretary of State of the State of Delaware on April 30, 2021 (the “Certificate of Designations”). Redemption Put Right – At any time on or after the sixth anniversary of the Closing Date, holders of the Series A Preferred Stock will have the right to cause the Company to redeem all or any portion of the Series A Preferred Stock in cash at an amount equal to the greater of (i) 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value and (ii) the amount per share that would be payable on an as-converted basis on such Series A Preferred Stock at the then-current Accrued Value, plus accrued PIK dividends that have not yet been added to the Accrued Value, and in either case of (i) or (ii) plus any unpaid cash dividends that would have otherwise been settled in cash in connection with such conversion (the greater of (i) and (ii), the “Redemption Price”). Redemption Call Right – At any time on or after the sixth anniversary of the Closing Date, the Company will have the right (but not the obligation) to redeem out of legally available funds and for cash consideration all (but not less than all) of the Series A Preferred Stock upon at least 30 days prior written notice at an amount equal to the Redemption Price. Board Nomination Rights – H.I.G. is entitled to nominate one individual for election to our Board of Directors so long as it continues to own at least 30% of the common stock issuable or issued upon conversion of the Series A Preferred Stock originally issued to it in the private placement. Under certain circumstances, H.I.G. also has the right to nominate an additional individual to our Board of Directors if we fail to maintain certain levels of commissions receivable or liquidity as further discussed below. Voting Rights – The Series A Preferred Stock will vote together with the common stock as a single class on all matters submitted to a vote of the holders of the common stock (subject to certain voting limitations set forth in, and the terms and conditions of, the Certificate of Designations). Each holder of Series A Preferred Stock shall be entitled to the number of votes, rounded down to the nearest whole number, equal to the product of (i) the aggregate Accrued Value of the issued and outstanding shares of Series A Preferred Stock divided by $69.684, which is the “Minimum Price” computed in accordance with the Certificate of Designations (as further described below), multiplied by (ii) a fraction, the numerator of which is the number of shares of Series A Preferred Stock held by such holder and the denominator of which is the aggregate number of issued and outstanding shares of Series A Preferred Stock. “Minimum Price” means the lower of: (i) the Nasdaq Official Closing Price per share of common stock on the Closing Date; or (ii) the average Nasdaq Official Closing Price per share of common stock for the five trading days immediately prior to the Closing Date. Holders of Series A Preferred Stock will have one vote per share on any matter on which the holders of the Series A Preferred Stock are entitled to vote separately as a class (subject to certain voting limitations set forth in the Certificate of Designations). Mandatory Conversion of the Series A Preferred Stock – At any time on or after the third anniversary of the Closing Date, if the volume-weighted average price per share of our common stock is greater than 167.5% of the then-current Conversion Price for 20 consecutive trading days in a 30-day trading day period, the Company will have the right to convert all, but not less than all, of the Series A Preferred Stock into common stock at a conversion rate with respect to each share of Series A Preferred Stock of (i) the Accrued Value plus accrued PIK dividends that have not yet been added to the Accrued Value, (ii) divided by the then applicable Conversion Price. Covenants and Liquidity Requirements – As long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, the consent of H.I.G. will be required for the Company to incur certain indebtedness and to take certain other corporate actions as set forth in the H.I.G. Investment Agreement. In addition, the Company is required to maintain an Asset Coverage Ratio (as defined in the H.I.G. Investment Agreement) of at least 2.0x (the “Minimum Asset Coverage Ratio”), which increased to 2.5x in August of 2023. The first measurement date of the 2.5x Minimum Asset Coverage Ratio was September 30, 2023. Additionally, the H.I.G. Investment Agreement requires the Company to maintain a Minimum Liquidity Amount (as defined in the H.I.G. Investment Agreement) for certain periods that ranges from $65.0 million to $125.0 million. Failure to maintain the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount as of the date or for the time period required by the H.I.G. Investment Agreement, for as long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, entitles H.I.G., subject to conditions and restrictions specified therein, to additional rights, including the right to nominate one additional member to the Company’s Board of Directors, the right to approve the Company’s annual budget, the right to approve hiring or termination of certain key executives and the right to approve the incurrence of certain indebtedness. As of September 30, 2023, we complied with the Minimum Liquidity Amount. However, our Asset Coverage Ratio was 2.3x as of September 30, 2023, and as a result, we did not meet the Minimum Asset Coverage Ratio. Our Series A Preferred Stock is considered temporary equity in our condensed consolidated financial statements. We have determined there are no material embedded features that require recognition as a derivative asset or liability. We recognized the Series A Preferred Stock at its stated amount less issuance costs of $11.0 million, or $214.0 million. As of September 30, 2023, the estimated Series A Preferred Stock redemption value equals 135% of the Accrued Value per share as of the redemption date, plus accrued PIK dividends that have not yet been added to the Accrued Value, which is significantly in excess of the fair value of the common stock into which the Series A Preferred Stock is convertible as of September 30, 2023. We have elected to apply the accretion method to adjust the carrying value of the Series A Preferred Stock to its redemption value at the earliest date of redemption, April 30, 2027. Amounts recognized to accrete the Series A Preferred Stock to its estimated redemption value are treated as a deemed dividend and are recorded as a reduction to retained earnings. The estimated redemption value will vary in subsequent periods due to the redemption put right described above and we have elected to recognize such changes prospectively. No shares of Series A Preferred Stock have been converted, and the Series A Preferred Stock was convertible into 3.4 million shares of common stock as of September 30, 2023. The following table summarizes the proceeds and changes to our Series A Preferred Stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of December 31, 2021 $ 232,592 Accrued paid-in-kind dividends 19,357 Change in preferred stock redemption value 11,335 Balance as of December 31, 2022 $ 263,284 Accrued paid-in-kind dividends 13,441 Change in preferred stock redemption value 12,158 Balance as of September 30, 2023 $ 288,883

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	Net Loss Per Share Attributable to Common Stockholders Our Series A Preferred Stock is considered a participating security which requires the use of the two-class method for the computation of basic and diluted per share amounts. Under the two-class method, earnings available to common stockholders for the period are allocated between common stockholders and participating securities according to dividends accumulated and participation rights in undistributed earnings. Net loss attributable to common stockholders is not allocated to the convertible preferred stock as the holder of the Series A Preferred Stock does not have a contractual obligation to share in losses. Basic net loss attributable to common stockholders per share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss available to common stockholders for the period by the weighted average number of common and common equivalent shares outstanding during the period. Diluted net loss attributable to common stockholders per share reflects all potential dilutive common stock equivalent shares, including conversion of preferred stock, stock options, restricted stock units and shares to be issued under our employee stock purchase program. The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ (47,243) $ (46,998) $ (108,206) $ (131,986) Denominator: Shares used in per share calculation – basic 28,114 27,346 27,863 27,329 Dilutive effect of common stock — — — — Shares used in per share calculation – diluted 28,114 27,346 27,863 27,329 Net loss attributable to common stockholders per share – basic and diluted $ (1.68) $ (1.72) $ (3.88) $ (4.83) For each of the three and nine months ended September 30, 2023 and 2022, we had securities outstanding that could potentially dilute per share amounts, but the shares from the assumed conversion or exercise of these securities were excluded in the computation of diluted net loss per share as their effect would have been anti-dilutive. The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Convertible preferred stock 3,368 3,130 3,315 3,083 Restricted stock units (1) 2,901 1,999 2,574 1,299 Common stock options 218 239 222 282 Employee stock purchase program 67 — 59 — Total 6,554 5,368 6,170 4,664 _________ (1) Amounts include market-based and performance-based restricted stock units.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Service and Licensing Obligations We have entered into service and licensing agreements with third party vendors to provide various services, including network access, equipment maintenance and software licensing. As the benefits of these agreements are experienced uniformly over the applicable contractual periods, we record the related service and licensing expenses on a straight-line basis, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Our future minimum payments under non-cancellable contractual service and licensing obligations as of September 30, 2023 were as follows (in thousands): For the Years Ending December 31, 2023 (remainder) $ 2,574 2024 4,911 2025 1,041 2026 — 2027 — Thereafter — Total $ 8,526 Operating Leases Refer to Note 10 – Leases for commitments related to our operating leases. Self-Insurance We provide comprehensive major medical benefits to our employees. Effective January 1, 2023, in the United States, we are self-insured for employee health insurance benefits up to $0.3 million per individual per year and a maximum claim liability of $13.6 million. As a result, we record a self-insurance liability based on claims filed and an estimate of claims incurred but not yet reported. As of September 30, 2023, we had a self-insurance liability balance of $2.0 million in the “Accrued compensation and benefits” line on our Condensed Consolidated Balance Sheet. We had no liability on our Condensed Consolidated Balance Sheet as of December 31, 2022 as our employee health insurance coverage was not self-insured at the time. Contingencies From time to time, we receive inquiries from governmental bodies and also may be subject to various legal proceedings and claims arising in the ordinary course of business. We assess contingencies to determine the degree of probability and range of possible loss for potential accrual in our condensed consolidated financial statements. An estimated loss contingency is accrued in the condensed consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. There was no material litigation-related accrual during the three and nine months ended September 30, 2023 or 2022. Legal proceedings or other contingencies could result in material costs, even if we ultimately prevail. Legal Proceedings Securities Class Action – On April 8, 2020 and April 30, 2020, two purported class action lawsuits were filed against the Company, its then-chief executive officer, Scott N. Flanders, its then-chief financial officer, Derek N. Yung, and its then-chief operating officer, David K. Francis in the United States District Court for the Northern District of California. The cases are captioned Patel v. eHealth, Inc., et al ., Case No. 5:20-cv-02395 (N.D. Cal.) and Bertrand v. eHealth, Inc. et al. , Case No. 4:20-cv-02967 (N.D. Cal.). The complaints allege, among other things, that the Company and Messrs. Flanders, Yung and Francis made materially false and misleading statements and/or failed to disclose material information regarding the Company’s accounting and modeling assumptions, rate of member churn and the Company’s profitability during the alleged class period of March 19, 2018 to April 7, 2020. The complaints allege that we and Messrs. Flanders, Yung and Francis violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) and Rule 10b-5 promulgated thereunder. The complaints seek compensatory and (in the Patel lawsuit) punitive damages, attorneys’ fees and costs, and such other relief as the court deems proper. On June 24, 2020, the Court consolidated the above-referenced matters under the caption In re eHealth Securities Litig. , Master File No. 4:20-cv-02395-JST (N.D. Cal.). The Court also appointed a lead plaintiff and lead counsel for the consolidated matter. An Amended Complaint was filed on August 25, 2020, which Defendants moved to dismiss on October 23, 2020. Defendants’ motion, which Plaintiff opposed, was granted in part and denied in part on August 12, 2021. The Court dismissed Plaintiff’s claims to the extent premised upon alleged misrepresentations or omissions relating to churn but denied Defendants’ motion with respect to alleged misstatements regarding purported operating costs. On October 1, 2021, the Company filed an Answer denying in part and admitting in part the remaining allegations and denying any wrongdoing. On November 11, 2021, Plaintiff’s counsel filed a suggestion of death with respect to the lead plaintiff Billy White. Plaintiff’s counsel published notice regarding the appointment of a new lead plaintiff on January 17, 2022. On November 9, 2022, the Court appointed Chicago & Vicinity Laborers’ District Council Pension Fund as the new lead plaintiff and approved plaintiff’s selection of counsel. On November 29, 2022, the new lead plaintiff and lead plaintiff’s counsel filed a supplement to the amended complaint, replacing the names of the prior lead plaintiff and counsel and incorporating new lead plaintiff’s previously filed certification. On December 22, 2022, the Company, Mr. Flanders, and Mr. Yung moved for judgment on the pleadings as to the remaining claims. Mr. Francis also moved for judgment on the pleadings the same day, and joined the motion by the Company, Mr. Flanders, and Mr. Yung. The motions for judgment on the pleadings were fully briefed by February 9, 2023 and were scheduled for a hearing on April 13, 2023. On April 5, 2023, the Court vacated the hearing on the motions and stated its intent to issue a decision based on the parties’ written briefing. On April 25, 2023, a consortium of putative class members (the “Alger Funds”) filed a motion to intervene in the case, prior to the expiration of the applicable statute of repose, to preserve their individual rights. On May 5, 2023, a defendants’ statement of non-opposition to Alger Funds’ limited motion to intervene and a stipulation with Alger Funds regarding same were filed. On September 28, 2023, the Court granted, with leave to amend, the Company’s motion for judgment on the pleadings as to all remaining claims, along with the similar motions of Mr. Flanders and Mr. Yung. The Court simultaneously dismissed, with prejudice and without leave to amend, all claims against Mr. Francis. On October 23, 2023, plaintiff filed a stipulation of dismissal order and notice, indicating that lead plaintiff would not file an amended complaint or appeal (a) the order granting in part and denying in part the motion to dismiss or (b) the order granting the motion for judgment on the pleadings. On October 25, 2023, the court entered the stipulated order, dismissing the case without leave to amend. There has not been subsequent follow-up from the Alger Funds. Derivative Actions – On July 7, 2020, a derivative lawsuit captioned  Chernet v. Flanders et al. , Case No. 3:20-cv-04477-SK (N.D. Cal.) (the “ Chernet” matter) was filed in the United States District Court for the Northern District of California. On October 13, 2020, a derivative lawsuit captioned Lincolnshire Police Pension Fund v. Flanders et al. , Case No. 20CV371555 (Cal. Super. Ct.) (the “ Lincolnshire” matter) was filed in the Superior Court of California, County of Santa Clara. The complaints were brought against the Company’s then-chief executive officer, Mr. Flanders, its then-chief financial officer, Mr. Yung, its then-chief operating officer, Mr. Francis, and the then-current members of the Board of Directors (collectively, the “Individual Defendants”), and name the Company as a nominal defendant. The complaints allege, among other things, that the Individual Defendants made or caused the Company to make materially false and misleading statements and/or failed to disclose material information regarding the Company’s accounting and modeling assumptions, rate of member churn, profitability and internal controls for the period of March 2018 through the present. The  Chernet  and  Lincolnshire  complaints purport to assert claims for breach of fiduciary duty, unjust enrichment and waste of corporate assets. The  Chernet  lawsuit also alleges that the Individual Defendants violated Sections 14(a), 10(b), and 20(a) of the Exchange Act and asserts claims for abuse of control and gross mismanagement. The  Chernet  and  Lincolnshire  complaints seek damages, restitution, attorneys’ fees and costs, and certain measures with respect to the Company’s corporate governance and internal procedures, and (in the  Lincolnshire  lawsuit) equitable and/or injunctive relief. On August 12, 2020, the court stayed the Chernet matter pending the resolution of the then-anticipated motion to dismiss the consolidated securities class action. On December 11, 2020, the court stayed the Lincolnshire matter, also pending the resolution of the motion to dismiss in the consolidated securities class action. On October 5, 2021, a third derivative lawsuit, captioned Badwal v. Flanders et al. , Case No. 4:21-cv-07795 (N.D. Cal.) (the “ Badwal” matter) was filed in the United States District Court for the Northern District of California. The  Badwal  complaint purports to assert a claim for breach of fiduciary duty, an insider trading claim, and violations of Section 14(a), 10(b) and 21D of the Exchange Act. The  Badwal  complaint seeks damages, declaratory relief, corporate governance measures, equitable and injunctive relief, restitution and disgorgement, and attorneys’ fees and costs. On November 29, 2021, the federal court consolidated the Chernet and Badwal matters under the caption In re eHealth, Inc. Stockholder Derivative Litigation (the “Federal Derivative Action”). On August 12, 2021, the court granted-in-part and denied-in-part defendants’ motion to dismiss the securities class action. In December 2021, the parties entered into a stipulation to further stay the Federal Derivative Action pending the appointment of a new lead plaintiff in the securities class action, which was so ordered by the court on December 14, 2021. As discussed above, November 9, 2022, the court appointed a new lead plaintiff in the securities class action. On December 9, 2022, plaintiffs in the Federal Derivative Action filed a verified consolidated stockholder derivative complaint on behalf of the Company against certain current and former members of its Board of Directors and certain of its officers. The complaint alleges breaches of fiduciary duties, insider trading, and violations of Sections 14(a), 10(b) and 21D of the Exchange Act. The complaint seeks damages, declaratory relief, corporate governance measures, equitable and injunctive relief, restitution and disgorgement, and attorneys’ fees and costs. On January 3, 2023, pursuant to a joint stipulation, the court ordered all proceedings in the Federal Derivative Action stayed pending the resolution of the securities class action. On July 28, 2023, the Lincolnshire matter was stayed pending

Segment and Geographic Informat

Segment and Geographic Information	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Operating Segments We report segment information based on how our chief executive officer, who is our chief operating decision maker (“CODM”), regularly reviews our operating results, allocates resources and makes decisions regarding our business operations. We evaluate our business performance and manage our operations as two distinct operating segments: Medicare and Individual, Family and Small Business. The performance measures of our segments include revenue and segment profit (loss). Please refer to Note 1 – Summary of Business and Significant Accounting Policies of the Notes to Consolidated Financial Statements in Part II, Item 8 of the Annual Report on Form 10-K for the year ended December 31, 2022 for our accounting policies relating to operating segments. The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Revenue: Medicare $ 55,523 $ 45,137 $ 172,787 $ 181,266 Individual, Family and Small Business 9,195 8,239 32,422 27,769 Total revenue $ 64,718 $ 53,376 $ 205,209 $ 209,035 Segment profit (loss): Medicare $ (17,471) $ (22,962) $ (25,539) $ (63,050) Individual, Family and Small Business 4,631 2,688 18,737 12,285 Segment profit (loss) (12,840) (20,274) (6,802) (50,765) Corporate (15,257) (12,795) (48,758) (40,382) Stock-based compensation expense (6,554) (5,144) (17,741) (15,934) Depreciation and amortization (4,745) (5,558) (15,141) (15,685) Impairment, restructuring and other charges — (4,498) — (10,690) Other income (expense), net (138) (647) (622) (2,835) Loss before income taxes $ (39,534) $ (48,916) $ (89,064) $ (136,291) There were no inter-segment revenue transactions for the periods presented. With the exception of contract assets – commissions receivable, which is presented by segment in Note 3 – Supplemental Financial Statement Information , our CODM does not separately evaluate assets by segment, and therefore, assets by segment are not presented. Geographic Information Our long-lived assets primarily consist of property and equipment, net and internally developed software. Our long-lived assets are attributed to the geographic location in which they are located. Long-lived assets by geographical area are summarized as follows (in thousands): September 30, 2023 December 31, 2022 United States $ 32,254 $ 37,915 China 249 381 Total $ 32,503 $ 38,296 Significant Customers Substantially all revenue for the three and nine months ended September 30, 2023 and 2022 was generated from customers located in the United States. Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Humana 31 % 17 % 28 % 18 % UnitedHealthCare (1) 22 % 27 % 22 % 22 % Aetna (1) 8 % 12 % 7 % 12 % Centene (1) 3 % 10 % 3 % 13 % ____________ (1) Percentages include the carriers’ subsidiaries.

Leases

Leases	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	Leases Our lease portfolio primarily consists of operating leases for office space and our leases have remaining lease terms of less than 1 year to 6 years. Certain of these leases have free or escalating rent payment provisions. We recognize lease expense on a straight-line basis over the terms of the leases, although actual cash payment obligations under certain of these agreements fluctuate over the terms of the agreements. Most leases include options to renew, and the exercise of these options is at our discretion. Subsequent to becoming a remote first workplace in the third quarter of 2022, we have executed several subleases of our office space in the United States. The subleases run through the remaining term of the primary leases. As of September 30, 2023, we expect to generate a total of $14.6 million in future sublease income through January 31, 2030. Sublease income is recorded on a straight-line basis as a reduction of lease expense in our Condensed Consolidated Statements of Comprehensive Loss. The components of operating lease costs for the three and nine months ended September 30, 2023 and 2022 were as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease expense $ 1,705 $ 1,905 $ 5,395 $ 5,729 Operating sublease income (518) (387) (1,675) (472) Total operating lease cost $ 1,187 $ 1,518 $ 3,720 $ 5,257 Supplemental information related to our leases are as follows (dollars in thousands): Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of operating lease liabilities $ 6,533 $ 5,878 Non-cash investing activities relating to operating lease right-of-use assets $ 1,285 $ — September 30, 2023 December 31, 2022 Weighted-average remaining lease term of operating leases 5.0 years 5.7 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.7 % 5.6 % As of September 30, 2023, maturities of our operating lease liabilities are as follows (in thousands): Year ending December 31, 2023 (remainder) $ 2,193 2024 8,889 2025 9,094 2026 7,760 2027 6,773 Thereafter 8,201 Total lease payments (1) $ 42,910 Less imputed interest (5,870) Total $ 37,040 ____________ (1) Non-cancellable sublease income for the remainder of 2023 and the years ending December 31, 2024, 2025, 2026, 2027 and thereafter of $0.4 million, $2.4 million, $2.6 million, $2.7 million, $2.8 million, and $3.8 million, respectively, are not included in the table above.

Impairment, Restructuring and O

Impairment, Restructuring and Other Charges	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Impairment, Restructuring and Other Charges	Impairment, Restructuring and Other Charges The following table details impairment, restructuring and other charges for each of the periods presented (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restructuring and reorganization charges $ — $ 764 $ — $ 6,956 Asset impairment charges — 3,734 — 3,734 Impairment, restructuring and other charges $ — $ 4,498 $ — $ 10,690 Restructuring Our restructuring and reorganization costs and liabilities consist primarily of severance, transition and other related costs. The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Balance at December 31, 2022 $ 366 Restructuring and reorganization charges — Payments (366) Balance at September 30, 2023 $ — During the three and nine months ended September 30, 2023, we incurred no pre-tax restructuring charges. As of September 30, 2023, we had no restructuring accrual on our Condensed Consolidated Balance Sheet. In the first half of 2022, we eliminated 339 full-time positions, which represented approximately 14% of our workforce, primarily within our customer care and enrollment group, and to a lesser extent, in our marketing and advertising, technology and content, and general and administrative groups, and, as a result, recorded pre-tax restructuring charges of $6.2 million in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. During the three months ended September 30, 2022, we incurred pre-tax restructuring charges of $0.8 million for additional eliminated positions, which resulted in a $7.0 million pre-tax restructuring charge for the nine months ended September 30, 2022 in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. For the three and nine months ended September 30, 2022, we recognized a non-cash, pre-tax asset impairment charge of $3.4 million related to the sublease of our office space in Santa Clara, California in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss. This charge was comprised of $2.5 million of operating lease right-of-use assets impairment and $0.9 million of property and equipment impairment. We also incurred $0.3 million of impairment charges related to abandoned in-process internally developed software during the quarter, which was also recognized in the “Impairment, restructuring and other charges” line in our Condensed Consolidated Statements of Comprehensive Loss.

Debt

Debt	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Debt	DebtOn February 28, 2022, we entered into a term loan credit agreement with Blue Torch Finance LLC, as administrative agent and collateral agent, and other lenders party thereto (the “Original Credit Agreement”). On August 16, 2022, we entered into an Amendment (the “Amendment”) to the Original Credit Agreement (as amended by the Amendment, the “Credit Agreement”). The Amendment replaced the LIBOR-based Adjusted Euro currency Rate (as defined in the Original Credit Agreement) with Adjusted Term SOFR (as defined in the Amendment) as a reference rate for loans under the Credit Agreement. The proceeds of the loans under the Credit Agreement may be used for working capital and general corporate purposes, to refinance our credit agreement with Royal Bank of Canada (“RBC”) and to pay fees and expenses in connection with the entry into the Credit Agreement. The Credit Agreement provides for a $70.0 million secured term loan credit facility. We incurred closing costs totaling $5.1 million, which were recorded as a direct deduction from the face of the loan on our Condensed Consolidated Balance Sheets. There were $2.7 million of unamortized issuance costs as of September 30, 2023. The carrying value of the term loan approximates the fair value, based on Level 2 inputs (observable market prices in less than active markets), as the interest rate is variable over the selected interest period and is similar to current rates at which we can borrow funds. The carrying value of the loan was $67.3 million as of September 30, 2023. The Original Credit Agreement bore interest, at our option, at either a rate based on the LIBOR for the applicable interest period or a base rate, in each case plus a margin. The base rate was the highest of the prime rate, the federal funds rates plus 0.50% and one month adjusted LIBOR plus 1.00%. The margin was 7.50% for LIBOR loans and 6.50% for base rate loans. After the Amendment, the loans under the Credit Agreement bear interest, at our option, at either a rate based on the Adjusted Term SOFR or a base rate, in each case plus a margin. The base rate is the highest of the prime rate, the federal funds rate plus 0.50% and three-month Adjusted Term SOFR plus 1.00%. The margin is 7.50% for Adjusted Term SOFR loans and 6.50% for base rate loans. As of September 30, 2023, the interest rate was 13.18%. For the three and nine months ended September 30, 2023, we incurred interest expense of $2.4 million and $6.8 million , respectively. For the three and nine months ended September 30, 2022, we incurred interest expense of $1.7 million and $3.9 million, respectively. Furthermore, as part of the Credit Agreement, we incur a $0.3 million fee per annum, payable annually. The outstanding obligations under the Credit Agreement are payable in full on the maturity date. The Credit Agreement matures in February 2025. We have the right to prepay the loans under the Credit Agreement in whole or in part at any time, subject, in the case of certain mandatory prepayments or any voluntary prepayment of the loans under the Credit Agreement after February 28, 2023, to an exit fee, which right we did not exercise. Our obligations under the Credit Agreement are guaranteed by certain of our material domestic subsidiaries and substantially all of our assets and the assets of such guarantors, in each case, subject to customary exclusion. Financial covenants in the Credit Agreement require that we maintain Liquidity (as defined in the Credit Agreement) at or above $25.0 million as of the last calendar day of any month. The Credit Agreement also requires that the outstanding amount as of the last calendar day of any month be less than 50% of our total contract assets - commissions receivables (i.e., both current and non-current commissions receivables). As of September 30, 2023, we were in compliance with our loan covenants. In the first quarter of 2022, in connection with entering into the Credit Agreement, we terminated our credit agreement with RBC, pursuant to which we had an up to $75 million revolving credit facility, and as a result, wrote off our remaining related debt issuance cost of $0.4 million. We had no outstanding borrowings under our agreement with RBC at the time of termination.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Loss before income taxes $ (39,534) $ (48,916) $ (89,064) $ (136,291) Benefit from income taxes (2,509) (9,767) (8,660) (26,898) Effective tax rate 6.3 % 20.0 % 9.7 % 19.7 % Our provision for income taxes during interim reporting periods has historically been calculated by applying an estimate of the annual effective tax rate to income (loss) before income taxes for the reporting period. Although we believe the use of the annual effective tax rate method to be appropriate for prior interim reporting periods, for the three and nine months ended September 30, 2023, we applied the actual effective tax rate, which reflects the actual taxes attributable to year-to-date losses, as allowed by ASC 740-270 “Income taxes, Interim Reporting.” We determined that since minor changes in estimated income or loss for fiscal 2023 would result in significant changes in the estimated annual effective tax rate, the discrete method would provide a more reliable estimate for the three and nine months ended September 30, 2023. For the three and nine months ended September 30, 2023, we recognized a benefit from income taxes of $2.5 million and $8.7 million, respectively, representing an effective tax rate of 6.3% and 9.7%, respectively, which was lower than the statutory federal tax rate primarily due to stock-based compensation adjustments, non-deductible lobbying expenses and changes in our valuation allowance, partially offset by research and development credits and state taxes. For the three and nine months ended September 30, 2022, we recognized a benefit from income taxes of $9.8 million and $26.9 million, respectively, representing an effective tax rate of 20.0% and 19.7%, respectively, which was lower than the statutory federal tax rate primarily due to stock-based compensation adjustments and non-deductible lobbying expenses, partially offset by research and development credits and state taxes. Assessing the realizability of our deferred tax assets is dependent upon several factors, including the likelihood and amount, if any, of future taxable income in relevant jurisdictions during the periods in which those temporary differences become deductible. We forecast taxable income by considering all available positive and negative evidence, including our history of operating income and losses and our financial plans and estimates that we use to manage the business. These assumptions require significant judgment about future taxable income. As a result, the amount of deferred tax assets considered realizable is subject to adjustment in future periods if estimates of future taxable income change. We continue to recognize our deferred tax assets as of September 30, 2023, as we believe it is more likely than not that such deferred tax assets will be realized, with the exception of certain net operating losses and credits for which there is increased uncertainty regarding our future taxable income and a lack of other sources of taxable income, which have a valuation allowance.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net loss	$ (37,025)	$ (23,501)	$ (19,878)	$ (39,149)	$ (37,502)	$ (32,742)	$ (80,404)	$ (109,393)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Summary of Business and Signi_2

Summary of Business and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Description of Business	Description of Business – eHealth, Inc., a Delaware corporation, and its consolidated subsidiaries (collectively, “eHealth”) is a leading private online health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. Our mission is to expertly guide consumers through their health insurance enrollment and related options, when, where and how they prefer. Our platform leverages technology to solve a critical problem in a large and growing market by aiding consumers in what has traditionally been a complex, confusing and opaque health insurance purchasing process. Our omnichannel consumer engagement platform differentiates our offering from other brokers and enables consumers to use our services online, by telephone with a licensed insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities. We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide. Our plan recommendation tool curates this broad plan selection by analyzing customer health-related information against plan data for insurance coverage fit. This tool is supported by a unified data platform and is available to our ecommerce customers and our benefit advisors. We strive to be the most trusted partner to the consumer in their life’s journey through the health insurance market.
Basis of Presentation	Basis of Presentation – The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023 and other condensed consolidated financial statements for the three and nine months ended September 30, 2023 and 2022 are unaudited. The Condensed Consolidated Balance Sheet data as of December 31, 2022 was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on March 1, 2023. The accompanying financial statements and related notes should be read in conjunction with the audited consolidated financial statements and related notes included in our Annual Report on Form 10-K. The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. The condensed consolidated financial statements include the accounts of eHealth, Inc. and its direct and indirect wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with those rules and regulations. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2022 and include all adjustments necessary for the fair presentation of our financial position as of September 30, 2023 and December 31, 2022, and our results of operations for the periods presented. The results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for any subsequent period or for the year ending December 31, 2023 and therefore, should not be relied upon as an indicator of future results.
Significant Accounting Policies, Estimates and Judgments	Significant Accounting Policies, Estimates and Judgments – The preparation of condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported and disclosed in the condensed consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates, including those related to, but not limited to, the fair value of investments, the commissions we expect to collect for each approved member cohort, valuation allowance for deferred income taxes, provision (benefit) for income taxes and the assumptions used in determining stock-based compensation. We base our estimates of the carrying value of certain assets and liabilities on historical experience and on various other assumptions that we believe to be reasonable. Actual results may differ from these estimates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements We did not adopt any new accounting pronouncements during the nine months ended September 30, 2023.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue by Segment	The table below depicts the disaggregation of revenue by product and is consistent with how we evaluate our financial performance (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Medicare Medicare Advantage $ 43,721 $ 37,454 $ 143,231 $ 152,061 Medicare Supplement 2,630 2,534 7,786 11,291 Medicare Part D 2,046 1,167 4,686 2,165 Total Medicare 48,397 41,155 155,703 165,517 Individual and Family (1) Non-Qualified Health Plans 1,560 1,991 6,904 5,970 Qualified Health Plans 681 714 4,084 2,975 Total Individual and Family 2,241 2,705 10,988 8,945 Ancillary Short-term 870 967 2,426 3,287 Dental 649 715 2,317 2,249 Vision 486 245 972 741 Other 555 674 1,788 1,803 Total Ancillary 2,560 2,601 7,503 8,080 Small Business 3,884 2,640 12,557 8,546 Commission Bonus and Other 157 (124) (1,323) (426) Total Commission Revenue 57,239 48,977 185,428 190,662 Other Revenue Sponsorship and Advertising Revenue 7,135 3,805 18,195 16,540 Other 344 594 1,586 1,833 Total Other Revenue 7,479 4,399 19,781 18,373 Total Revenue $ 64,718 $ 53,376 $ 205,209 $ 209,035 _____________ (1) We define our individual and family plan offerings as major medical individual and family health insurance plans, which do not include Medicare-related, small business or ancillary plans. Individual and family plans include both qualified and non-qualified plans. Qualified health plans meet the requirements of the Affordable Care Act and are offered through the government-run health insurance exchange in the relevant jurisdiction. Non-qualified health plans do not meet the requirements of the Affordable Care Act and are not offered through the government-run health insurance exchange in the relevant jurisdiction. Individuals that purchase non-qualified health plans cannot receive a subsidy in connection with the purchase of non-qualified plans. Commission revenue by segment is presented in the table below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Medicare Commission revenue from members approved during the period $ 39,169 $ 39,652 $ 131,792 $ 173,790 Net commission revenue from members approved in prior periods (1) 9,291 1,685 22,746 (9,052) Total Medicare segment commission revenue $ 48,460 $ 41,337 $ 154,538 $ 164,738 Individual, Family and Small Business Commission revenue from members approved during the period $ 3,829 $ 3,600 $ 13,835 $ 14,254 Commission revenue from renewals of small business members during the period 2,028 2,200 7,299 7,281 Net commission revenue from members approved in prior periods (1) 2,922 1,840 9,756 4,389 Total Individual, Family and Small Business segment commission revenue $ 8,779 $ 7,640 $ 30,890 $ 25,924 Total commission revenue from members approved during the period $ 42,998 $ 43,252 $ 145,627 $ 188,044 Commission revenue from renewals of small business members during the period 2,028 2,200 7,299 7,281 Total net commission revenue from members approved in prior periods (1)(2) 12,213 3,525 32,502 (4,663) Total commission revenue $ 57,239 $ 48,977 $ 185,428 $ 190,662 _____________ (1) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. (2) The impacts of total net commission revenue from members approved in prior periods were $0.43 and $0.13 per basic and diluted share for the three months ended September 30, 2023 and 2022, respectively. The impacts of total net commission revenue from members approved in prior periods were $1.17 and $(0.17) per basic and diluted share for the nine months ended September 30, 2023 and 2022, respectively. The total reductions to revenue from members approved in prior periods were $0.8 million and $2.1 million for the three months ended September 30, 2023 and 2022, respectively, and $3.7 million and $15.8 million for the nine months ended September 30, 2023 and 2022, respectively. These reductions to revenue primarily relate to the Medicare segment.

Supplemental Financial Statem_2

Supplemental Financial Statement Information (Tables)	9 Months Ended
	Sep. 30, 2023
Balance Sheet Related Disclosures [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): September 30, 2023 December 31, 2022 Cash $ 22,835 $ 17,776 Cash equivalents 129,283 126,625 Cash and cash equivalents 152,118 144,401 Restricted cash 3,090 3,239 Total cash, cash equivalents and restricted cash $ 155,208 $ 147,640
Schedule of Cash, Cash Equivalents and Restricted Cash	Our cash, cash equivalents and restricted cash balances are summarized as follows (in thousands): September 30, 2023 December 31, 2022 Cash $ 22,835 $ 17,776 Cash equivalents 129,283 126,625 Cash and cash equivalents 152,118 144,401 Restricted cash 3,090 3,239 Total cash, cash equivalents and restricted cash $ 155,208 $ 147,640
Schedule of Change in Allowance for Credit Loss	The change in the allowance for credit losses is summarized as follows (in thousands): September 30, 2023 December 31, 2022 Beginning balance $ 2,398 $ 2,198 Change in allowance (433) 200 Ending balance $ 1,965 $ 2,398
Schedule of Contract Assets - Commissions Receivable	Our contract assets – commissions receivable activities, net of credit loss allowances, are summarized as follows (in thousands): Medicare Segment IFP/SMB Segment Total Beginning balance at December 31, 2022 $ 817,043 $ 67,261 $ 884,304 Commission revenue from members approved during the period 131,792 13,835 145,627 Commission revenue from renewals of small business members during the period — 7,299 7,299 Net commission revenue from members approved in prior periods 22,746 9,756 32,502 Cash receipts (258,724) (30,865) (289,589) Net change in credit loss allowance 396 37 433 Ending balance at September 30, 2023 $ 713,253 $ 67,323 $ 780,576
Schedule of Credit Risk	Carriers that represented 10% or more of our total contract assets – commissions receivable and accounts receivable balances are summarized as follows: September 30, 2023 December 31, 2022 Humana 27 % 26 % UnitedHealthCare (1) 25 % 24 % Aetna (1) 15 % 16 % _____________ (1) Percentages include the carriers’ subsidiaries.
Schedule of Prepaid Expenses and Other Current Assets	Our prepaid expenses and other current assets are summarized as follows (in thousands): September 30, 2023 December 31, 2022 Prepaid expenses $ 12,629 $ 2,858 Prepaid software and maintenance contracts 6,304 5,211 Prepaid licenses 3,289 1,116 Prepaid insurance 775 1,893 Other current assets 236 223 Prepaid expenses and other current assets $ 23,233 $ 11,301

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	We classify the inputs used to measure fair value into the following hierarchy: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities; unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability. Level 3 Unobservable inputs for the asset or liability.
Summary of Financial Assets Measured at Fair Value on a Recurring Basis	Our financial assets measured at fair value on a recurring basis are summarized below by their classification within the fair value hierarchy (in thousands): September 30, 2023 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 502 $ 502 $ — $ — $ 502 Commercial paper 113,884 — 113,884 — 113,884 Agency bonds 14,897 — 14,897 — 14,897 Short-term marketable securities Commercial paper 8,469 — 8,469 — 8,469 Total assets measured at fair value $ 137,752 $ 502 $ 137,250 $ — $ 137,752 December 31, 2022 Carrying Value Level 1 Level 2 Level 3 Total Assets Cash equivalents Money market funds $ 13,015 $ 13,015 $ — $ — $ 13,015 Commercial paper 112,268 — 112,268 — 112,268 Agency bonds 1,342 — 1,342 — 1,342 Total assets measured at fair value $ 126,625 $ 13,015 $ 113,610 $ — $ 126,625
Summary of Contractual Maturities	The following table summarizes our cash equivalents and available-for-sale debt securities by contractual maturity (in thousands): As of September 30, 2023 As of December 31, 2022 Amortized Cost Fair Value Amortized Cost Fair Value Due in 1 year $ 137,796 $ 137,752 $ 126,664 $ 126,625
Summary of Unrealized Gains and Losses	Unrealized gains and losses on available-for-sale debt securities that are not credit related are included in accumulated other comprehensive income (loss) and summarized as follows (in thousands): September 30, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 502 $ — $ — $ 502 Commercial paper 113,927 — (43) 113,884 Agency bonds 14,895 2 — 14,897 Short-term marketable securities Commercial paper 8,472 — (3) 8,469 Total $ 137,796 $ 2 $ (46) $ 137,752 December 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Cash equivalents Money market funds $ 13,015 $ — $ — $ 13,015 Commercial paper 112,307 — (39) 112,268 Agency bonds 1,342 — — 1,342 Total $ 126,664 $ — $ (39) $ 126,625

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Schedule of Stock-based Compensation Expense by Award Type	Our stock-based compensation expense is summarized as follows by award types for the periods presented below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restricted stock units (1) $ 6,098 $ 4,687 $ 16,559 $ 14,625 Common stock options 333 313 899 864 Employee stock purchase program 123 144 283 445 Total stock-based compensation expense $ 6,554 $ 5,144 $ 17,741 $ 15,934 Related tax benefit recognized $ 1,543 $ 1,194 $ 4,162 $ 3,702 _________ (1) Amounts include market-based and performance-based restricted stock units.
Schedule of Stock-based Compensation Expense by Operating Function	The following table summarizes stock-based compensation expense by operating function for the periods presented below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Marketing and advertising $ 605 $ 570 $ 1,598 $ 1,311 Customer care and enrollment 836 610 2,229 1,576 Technology and content 1,306 1,341 3,384 5,012 General and administrative 3,807 2,623 10,530 8,035 Total stock-based compensation expense $ 6,554 $ 5,144 $ 17,741 $ 15,934 Amount capitalized for internal-use software 243 487 880 1,493 Total stock-based compensation $ 6,797 $ 5,631 $ 18,621 $ 17,427

Convertible Preferred Stock (Ta

Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2023
Temporary Equity Disclosure [Abstract]
Summary of Convertible Preferred Stock	The following table summarizes the proceeds and changes to our Series A Preferred Stock (in thousands): Gross proceeds $ 225,000 Less: issuance costs (10,975) Net proceeds $ 214,025 Balance as of December 31, 2021 $ 232,592 Accrued paid-in-kind dividends 19,357 Change in preferred stock redemption value 11,335 Balance as of December 31, 2022 $ 263,284 Accrued paid-in-kind dividends 13,441 Change in preferred stock redemption value 12,158 Balance as of September 30, 2023 $ 288,883

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss attributable to common stockholders per share (in thousands, except per share amounts): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Numerator: Net loss attributable to common stockholders $ (47,243) $ (46,998) $ (108,206) $ (131,986) Denominator: Shares used in per share calculation – basic 28,114 27,346 27,863 27,329 Dilutive effect of common stock — — — — Shares used in per share calculation – diluted 28,114 27,346 27,863 27,329 Net loss attributable to common stockholders per share – basic and diluted $ (1.68) $ (1.72) $ (3.88) $ (4.83)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The number of outstanding anti-dilutive shares that were excluded from the computation of diluted net loss per share consisted of the following (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Convertible preferred stock 3,368 3,130 3,315 3,083 Restricted stock units (1) 2,901 1,999 2,574 1,299 Common stock options 218 239 222 282 Employee stock purchase program 67 — 59 — Total 6,554 5,368 6,170 4,664 _________ (1) Amounts include market-based and performance-based restricted stock units.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments For Contractual Obligations	Our future minimum payments under non-cancellable contractual service and licensing obligations as of September 30, 2023 were as follows (in thousands): For the Years Ending December 31, 2023 (remainder) $ 2,574 2024 4,911 2025 1,041 2026 — 2027 — Thereafter — Total $ 8,526

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The results of our operating segments are summarized for the periods presented below (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Revenue: Medicare $ 55,523 $ 45,137 $ 172,787 $ 181,266 Individual, Family and Small Business 9,195 8,239 32,422 27,769 Total revenue $ 64,718 $ 53,376 $ 205,209 $ 209,035 Segment profit (loss): Medicare $ (17,471) $ (22,962) $ (25,539) $ (63,050) Individual, Family and Small Business 4,631 2,688 18,737 12,285 Segment profit (loss) (12,840) (20,274) (6,802) (50,765) Corporate (15,257) (12,795) (48,758) (40,382) Stock-based compensation expense (6,554) (5,144) (17,741) (15,934) Depreciation and amortization (4,745) (5,558) (15,141) (15,685) Impairment, restructuring and other charges — (4,498) — (10,690) Other income (expense), net (138) (647) (622) (2,835) Loss before income taxes $ (39,534) $ (48,916) $ (89,064) $ (136,291)
Schedule of Long Lived Assets by Geographical Areas	Long-lived assets by geographical area are summarized as follows (in thousands): September 30, 2023 December 31, 2022 United States $ 32,254 $ 37,915 China 249 381 Total $ 32,503 $ 38,296
Schedule of Revenue by Major Customers	Carriers representing 10% or more of our total revenue are summarized as follows: Three Months Ended Nine Months Ended 2023 2022 2023 2022 Humana 31 % 17 % 28 % 18 % UnitedHealthCare (1) 22 % 27 % 22 % 22 % Aetna (1) 8 % 12 % 7 % 12 % Centene (1) 3 % 10 % 3 % 13 % ____________ (1) Percentages include the carriers’ subsidiaries.

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of Lease Cost	The components of operating lease costs for the three and nine months ended September 30, 2023 and 2022 were as follows (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Operating lease expense $ 1,705 $ 1,905 $ 5,395 $ 5,729 Operating sublease income (518) (387) (1,675) (472) Total operating lease cost $ 1,187 $ 1,518 $ 3,720 $ 5,257 Supplemental information related to our leases are as follows (dollars in thousands): Nine Months Ended 2023 2022 Cash paid for amounts included in the measurement of operating lease liabilities $ 6,533 $ 5,878 Non-cash investing activities relating to operating lease right-of-use assets $ 1,285 $ — September 30, 2023 December 31, 2022 Weighted-average remaining lease term of operating leases 5.0 years 5.7 years Weighted-average discount rate used to recognize operating lease right-of-use-assets 5.7 % 5.6 %
Schedule of Operating Lease Maturities	As of September 30, 2023, maturities of our operating lease liabilities are as follows (in thousands): Year ending December 31, 2023 (remainder) $ 2,193 2024 8,889 2025 9,094 2026 7,760 2027 6,773 Thereafter 8,201 Total lease payments (1) $ 42,910 Less imputed interest (5,870) Total $ 37,040 ____________ (1) Non-cancellable sublease income for the remainder of 2023 and the years ending December 31, 2024, 2025, 2026, 2027 and thereafter of $0.4 million, $2.4 million, $2.6 million, $2.7 million, $2.8 million, and $3.8 million, respectively, are not included in the table above.

Impairment, Restructuring and_2

Impairment, Restructuring and Other Charges (Tables)	9 Months Ended
	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Summary of Impairment, Restructuring and Other Charges (Recoveries)	The following table details impairment, restructuring and other charges for each of the periods presented (in thousands): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Restructuring and reorganization charges $ — $ 764 $ — $ 6,956 Asset impairment charges — 3,734 — 3,734 Impairment, restructuring and other charges $ — $ 4,498 $ — $ 10,690
Summary of Restructuring and Other Related Liabilities	The following table summarizes the cash-based restructuring and reorganization related liabilities (in thousands): Balance at December 31, 2022 $ 366 Restructuring and reorganization charges — Payments (366) Balance at September 30, 2023 $ —

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense	The following table summarizes our benefit from income taxes and our effective tax rates for the periods presented below (in thousands, except effective tax rate): Three Months Ended Nine Months Ended 2023 2022 2023 2022 Loss before income taxes $ (39,534) $ (48,916) $ (89,064) $ (136,291) Benefit from income taxes (2,509) (9,767) (8,660) (26,898) Effective tax rate 6.3 % 20.0 % 9.7 % 19.7 %

Summary of Business and Signi_3

Summary of Business and Significant Accounting Policies (Details)	Sep. 30, 2023 insurance_carrier
Accounting Policies [Abstract]
Number of health insurance carriers (more than)	180

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 64,718	$ 53,376	$ 205,209	$ 209,035
Medicare
Disaggregation of Revenue [Line Items]
Total revenue	48,397	41,155	155,703	165,517
Medicare | Medicare Advantage
Disaggregation of Revenue [Line Items]
Total revenue	43,721	37,454	143,231	152,061
Medicare | Medicare Supplement
Disaggregation of Revenue [Line Items]
Total revenue	2,630	2,534	7,786	11,291
Medicare | Medicare Part D
Disaggregation of Revenue [Line Items]
Total revenue	2,046	1,167	4,686	2,165
Individual and Family
Disaggregation of Revenue [Line Items]
Total revenue	2,241	2,705	10,988	8,945
Individual and Family | Non-Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	1,560	1,991	6,904	5,970
Individual and Family | Qualified Health Plans
Disaggregation of Revenue [Line Items]
Total revenue	681	714	4,084	2,975
Ancillary
Disaggregation of Revenue [Line Items]
Total revenue	2,560	2,601	7,503	8,080
Ancillary | Short-term
Disaggregation of Revenue [Line Items]
Total revenue	870	967	2,426	3,287
Ancillary | Dental
Disaggregation of Revenue [Line Items]
Total revenue	649	715	2,317	2,249
Ancillary | Vision
Disaggregation of Revenue [Line Items]
Total revenue	486	245	972	741
Ancillary | Other
Disaggregation of Revenue [Line Items]
Total revenue	555	674	1,788	1,803
Small Business
Disaggregation of Revenue [Line Items]
Total revenue	3,884	2,640	12,557	8,546
Commission Bonus and Other
Disaggregation of Revenue [Line Items]
Total revenue	157	(124)	(1,323)	(426)
Total Commission Revenue
Disaggregation of Revenue [Line Items]
Total revenue	57,239	48,977	185,428	190,662
Other Revenue
Disaggregation of Revenue [Line Items]
Total revenue	7,479	4,399	19,781	18,373
Other Revenue | Sponsorship and Advertising Revenue
Disaggregation of Revenue [Line Items]
Total revenue	7,135	3,805	18,195	16,540
Other Revenue | Other
Disaggregation of Revenue [Line Items]
Total revenue	$ 344	$ 594	$ 1,586	$ 1,833

Revenue - Commission Revenue by

Revenue - Commission Revenue by Segment (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 64,718	$ 53,376	$ 205,209	$ 209,035
Basic (in dollars per share)	$ (1.68)	$ (1.72)	$ (3.88)	$ (4.83)
Diluted (in dollars per share)	$ (1.68)	$ (1.72)	$ (3.88)	$ (4.83)
Commission
Disaggregation of Revenue [Line Items]
Total revenue	$ 57,239	$ 48,977	$ 185,428	$ 190,662
Commission revenue from members approved during the period
Disaggregation of Revenue [Line Items]
Total revenue	42,998	43,252	145,627	188,044
Commission revenue from renewals of small business members during the period
Disaggregation of Revenue [Line Items]
Total revenue	2,028	2,200	7,299	7,281
Total Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 12,213	$ 3,525	$ 32,502	$ (4,663)
Basic (in dollars per share)	$ 0.43	$ 0.13	$ 1.17	$ (0.17)
Diluted (in dollars per share)	$ 0.43	$ 0.13	$ 1.17	$ (0.17)
Change in revenue	$ (800)	$ (2,100)	$ (3,700)	$ (15,800)
Medicare | Commission
Disaggregation of Revenue [Line Items]
Total revenue	48,460	41,337	154,538	164,738
Medicare | Commission revenue from members approved during the period
Disaggregation of Revenue [Line Items]
Total revenue	39,169	39,652	131,792	173,790
Medicare | Commission revenue from renewals of small business members during the period
Disaggregation of Revenue [Line Items]
Total revenue			0
Medicare | Total Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	9,291	1,685	22,746	(9,052)
Individual, Family and Small Business | Commission
Disaggregation of Revenue [Line Items]
Total revenue	8,779	7,640	30,890	25,924
Individual, Family and Small Business | Commission revenue from members approved during the period
Disaggregation of Revenue [Line Items]
Total revenue	3,829	3,600	13,835	14,254
Individual, Family and Small Business | Commission revenue from renewals of small business members during the period
Disaggregation of Revenue [Line Items]
Total revenue	2,028	2,200	7,299	7,281
Individual, Family and Small Business | Total Net Commission Revenue from Members Approved in Prior Periods
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,922	$ 1,840	$ 9,756	$ 4,389

Supplemental Financial Statem_3

Supplemental Financial Statement Information - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Balance Sheet Related Disclosures [Abstract]
Cash	$ 22,835	$ 17,776
Cash equivalents	129,283	126,625
Cash and cash equivalents	152,118	144,401
Restricted cash	3,090	3,239
Total cash, cash equivalents and restricted cash	$ 155,208	$ 147,640	$ 163,497	$ 85,165

Supplemental Financial Statem_4

Supplemental Financial Statement Information - Narrative (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Line Items]
Restricted cash	$ 3,090,000	$ 3,239,000
Write-off	0	$ 0
China
Cash and Cash Equivalents [Line Items]
Deposits	$ 2,800,000

Supplemental Financial Statem_5

Supplemental Financial Statement Information - Schedule of Allowance for Credit Loss (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Contract with Customer, Asset, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 2,398	$ 2,198
Change in allowance	(433)	200
Ending balance	$ 1,965	$ 2,398

Supplemental Financial Statem_6

Supplemental Financial Statement Information - Schedule of Commissions Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance at December 31, 2022			$ 884,304
Total revenue	$ 64,718	$ 53,376	205,209	$ 209,035
Cash receipts			(289,589)
Net change in credit loss allowance			433
Ending balance at September 30, 2023	780,576		780,576
Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance at December 31, 2022			817,043
Cash receipts			(258,724)
Net change in credit loss allowance			396
Ending balance at September 30, 2023	713,253		713,253
IFP/SMB Segment
Change in Contract with Customer, Asset [Roll Forward]
Beginning balance at December 31, 2022			67,261
Cash receipts			(30,865)
Net change in credit loss allowance			37
Ending balance at September 30, 2023	67,323		67,323
Commission revenue from members approved during the period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	42,998	43,252	145,627	188,044
Commission revenue from members approved during the period | Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	39,169	39,652	131,792	173,790
Commission revenue from members approved during the period | IFP/SMB Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	3,829	3,600	13,835	14,254
Commission revenue from renewals of small business members during the period
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	2,028	2,200	7,299	7,281
Commission revenue from renewals of small business members during the period | Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue			0
Commission revenue from renewals of small business members during the period | IFP/SMB Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	2,028	2,200	7,299	7,281
Net commission revenue from members approved in prior periods
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	12,213	3,525	32,502	(4,663)
Net commission revenue from members approved in prior periods | Medicare Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	9,291	1,685	22,746	(9,052)
Net commission revenue from members approved in prior periods | IFP/SMB Segment
Change in Contract with Customer, Asset [Roll Forward]
Total revenue	$ 2,922	$ 1,840	$ 9,756	$ 4,389

Supplemental Financial Statem_7

Supplemental Financial Statement Information - Schedule of Credit Risk (Details) - Customer Concentration Risk - Accounts Receivable	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Humana
Concentration Risk [Line Items]
Major customer revenue, percentage	27%	26%
UnitedHealthCare
Concentration Risk [Line Items]
Major customer revenue, percentage	25%	24%
Aetna
Concentration Risk [Line Items]
Major customer revenue, percentage	15%	16%

Supplemental Financial Statem_8

Supplemental Financial Statement Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Balance Sheet Related Disclosures [Abstract]
Prepaid expenses	$ 12,629	$ 2,858
Prepaid software and maintenance contracts	6,304	5,211
Prepaid licenses	3,289	1,116
Prepaid insurance	775	1,893
Other current assets	236	223
Prepaid expenses and other current assets	$ 23,233	$ 11,301

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets
Short-term marketable securities	$ 8,469	$ 0
Commercial paper
Assets
Short-term marketable securities	8,469
Money market funds
Assets
Cash equivalents	502	13,015
Commercial paper
Assets
Cash equivalents	113,884	112,268
Agency bonds
Assets
Cash equivalents	14,897	1,342
Recurring | Level 1
Assets
Total assets measured at fair value	502	13,015
Recurring | Level 2
Assets
Total assets measured at fair value	137,250	113,610
Recurring | Level 3
Assets
Total assets measured at fair value	0	0
Recurring | Carrying Value
Assets
Total assets measured at fair value	137,752	126,625
Recurring | Fair Value
Assets
Total assets measured at fair value	137,752	126,625
Recurring | Commercial paper | Level 1
Assets
Short-term marketable securities	0
Recurring | Commercial paper | Level 2
Assets
Short-term marketable securities	8,469
Recurring | Commercial paper | Level 3
Assets
Short-term marketable securities	0
Recurring | Commercial paper | Carrying Value
Assets
Short-term marketable securities	8,469
Recurring | Commercial paper | Fair Value
Assets
Short-term marketable securities	8,469
Recurring | Money market funds | Level 1
Assets
Cash equivalents	502	13,015
Recurring | Money market funds | Level 2
Assets
Cash equivalents	0	0
Recurring | Money market funds | Level 3
Assets
Cash equivalents	0	0
Recurring | Money market funds | Carrying Value
Assets
Cash equivalents	502	13,015
Recurring | Money market funds | Fair Value
Assets
Cash equivalents	502	13,015
Recurring | Commercial paper | Level 1
Assets
Cash equivalents	0	0
Recurring | Commercial paper | Level 2
Assets
Cash equivalents	113,884	112,268
Recurring | Commercial paper | Level 3
Assets
Cash equivalents	0	0
Recurring | Commercial paper | Carrying Value
Assets
Cash equivalents	113,884	112,268
Recurring | Commercial paper | Fair Value
Assets
Cash equivalents	113,884	112,268
Recurring | Agency bonds | Level 1
Assets
Cash equivalents	0	0
Recurring | Agency bonds | Level 2
Assets
Cash equivalents	14,897	1,342
Recurring | Agency bonds | Level 3
Assets
Cash equivalents	0	0
Recurring | Agency bonds | Carrying Value
Assets
Cash equivalents	14,897	1,342
Recurring | Agency bonds | Fair Value
Assets
Cash equivalents	$ 14,897	$ 1,342

Fair Value Measurements - Contr

Fair Value Measurements - Contractual Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Amortized Cost
Due in 1 year	$ 137,796	$ 126,664
Fair Value
Due in 1 year	$ 137,752	$ 126,625

Fair Value Measurements - Unrea

Fair Value Measurements - Unrealized Gains and Losses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Cash equivalents
Cash and cash equivalents	$ 152,118	$ 144,401
Short-term marketable securities
Fair Value	8,469	0
Total	137,796	126,664
Unrealized Gains	2	0
Unrealized Losses	(46)	(39)
Fair Value	137,752	126,625
Commercial paper
Short-term marketable securities
Amortized Cost	8,472
Unrealized Gains	0
Unrealized Losses	(3)
Fair Value	8,469
Money market funds
Cash equivalents
Cash and cash equivalents	502	13,015
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	502	13,015
Commercial paper
Cash equivalents
Cash and cash equivalents	113,927	112,307
Unrealized Gains	0	0
Unrealized Losses	(43)	(39)
Fair Value	113,884	112,268
Agency bonds
Cash equivalents
Cash and cash equivalents	14,895	1,342
Unrealized Gains	2	0
Unrealized Losses	0	0
Fair Value	$ 14,897	$ 1,342

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - security	Sep. 30, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Number of securities in net loss positions	28	26

Equity - Narrative (Details)

Equity - Narrative (Details) - shares	1 Months Ended		3 Months Ended		9 Months Ended		24 Months Ended
	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 22, 2021
Equity, Class of Treasury Stock [Line Items]
Shares reserved for future issuance (in shares)								400,000
Additional shares reserved (in shares)	1,500,000	500,000
Granted (in shares)							2,000,000
Number of shares repurchased under share repurchase plan (in shares)			0	0	0	0
Treasury stock (in shares)	12,400,000		12,700,000	12,400,000	12,700,000	12,400,000	12,700,000
Treasury shares that were previously surrendered by employees to satisfy tax withholdings (in shares)					2,000,000	1,700,000
Previous share repurchase programs
Equity, Class of Treasury Stock [Line Items]
Number of shares repurchased under share repurchase plan (in shares)					10,700,000

Equity - Schedule of Stock-Base

Equity - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 6,554	$ 5,144	$ 17,741	$ 15,934
Related tax benefit recognized	1,543	1,194	4,162	3,702
Amount capitalized for internal-use software	243	487	880	1,493
Total stock-based compensation	6,797	5,631	18,621	17,427
Marketing and advertising
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	605	570	1,598	1,311
Customer care and enrollment
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	836	610	2,229	1,576
Technology and content
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1,306	1,341	3,384	5,012
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	3,807	2,623	10,530	8,035
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	6,098	4,687	16,559	14,625
Common stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	333	313	899	864
Employee stock purchase program
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 123	$ 144	$ 283	$ 445

Convertible Preferred Stock - N

Convertible Preferred Stock - Narrative (Details) $ / shares in Units, $ in Thousands				3 Months Ended	6 Months Ended	9 Months Ended
	Apr. 30, 2024 day	Jun. 30, 2023	Apr. 30, 2021 USD ($) state vote $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2021 $ / shares	Sep. 30, 2023 USD ($) $ / shares shares	Apr. 30, 2027 day	Aug. 31, 2023	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Feb. 17, 2021 USD ($)
Temporary Equity [Line Items]
Sale of stock, shares issued (in shares) | shares			2,250,000
Preferred stock, par value (in dollars per share) | $ / shares			$ 0.001
Gross proceeds			$ 225,000
Carrying amount			214,000			$ 288,883			$ 263,284	$ 232,592
Payments of stock issuance costs			$ 10,975
Dividend rate		8%			8%
Stated value (in dollars per share) | $ / shares					$ 100
Dividend rate, payable-in-kind		6%
Dividend rate, cash		2%
Conversion rate (in dollars per share) | $ / shares						$ 79.5861
Redemption put right, percentage of accrued value						135%
Number of votes per share | vote			1
Asset coverage ratio						230%		250%			200%
Shares converted (in shares) | shares						0
Accrued paid-in-kind dividends, common stock equivalent, as-converted (in shares) | shares						3,400,000
Series A Preferred Stock
Temporary Equity [Line Items]
Dividends, cash				$ 900
Dividends payable						$ 1,300
Aggregate accrued value divisor (in dollars per share) | $ / shares			$ 69.684
Minimum
Temporary Equity [Line Items]
Minimum liquidity amount											$ 65,000
Maximum
Temporary Equity [Line Items]
Minimum liquidity amount											$ 125,000
H.I.G
Temporary Equity [Line Items]
Number of nominations to board of directors | state			1
Minimum common stock ownership percentage needed to nominate individual to board of directors			30%
Minimum ownership percentage			30%								30%
Forecast
Temporary Equity [Line Items]
Redemption put right, percentage of accrued value							135%
Redemption call right, number of days for written notice | day							30
Threshold percentage of conversion price	167.50%
Threshold consecutive trading days | day	20
Threshold trading days | day	30

Convertible Preferred Stock - S

Convertible Preferred Stock - Summary of Stock (Details) - USD ($) $ in Thousands		9 Months Ended	12 Months Ended
	Apr. 30, 2021	Sep. 30, 2023	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Gross proceeds	$ 225,000
Less: issuance costs	(10,975)
Net proceeds	214,025
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance		$ 263,284	$ 232,592
Accrued paid-in-kind dividends		13,441	19,357
Change in preferred stock redemption value		12,158	11,335
Ending balance	$ 214,000	$ 288,883	$ 263,284

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net loss attributable to common stockholders basic	$ (47,243)	$ (46,998)	$ (108,206)	$ (131,986)
Net loss attributable to common stockholders diluted	$ (47,243)	$ (46,998)	$ (108,206)	$ (131,986)
Denominator:
Shares used in per share calculation - basic (in shares)	28,114	27,346	27,863	27,329
Dilutive effect of common stock (in shares)	0	0	0	0
Shares used in per share calculation - diluted (in shares)	28,114	27,346	27,863	27,329
Net loss attributable to common stockholders per share - basic (in dollars per share)	$ (1.68)	$ (1.72)	$ (3.88)	$ (4.83)
Net loss attributable to common stockholders per share - diluted (in dollars per share)	$ (1.68)	$ (1.72)	$ (3.88)	$ (4.83)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-Dilutive Shares Excluded from Computation Of Net Income Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	6,554	5,368	6,170	4,664
Convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	3,368	3,130	3,315	3,083
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,901	1,999	2,574	1,299
Common stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	218	239	222	282
Employee stock purchase program
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	67	0	59	0

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Obligations (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2023 (remainder)	$ 2,574
2024	4,911
2025	1,041
2026	0
2027	0
Thereafter	0
Total	$ 8,526

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details)	1 Months Ended
	Apr. 30, 2020 claim	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Self insurance reserve, maximum benefits per employee		$ 300,000
Self insurance maximum claim liability		13,600,000
Self insurance reserve		$ 2,000,000	$ 0
New claims filed | claim	2

Segment and Geographic Inform_3

Segment and Geographic Information - Segment Operating Results (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment			2
Total revenue	$ 64,718	$ 53,376	$ 205,209	$ 209,035
Stock-based compensation expense	(6,554)	(5,144)	(17,741)	(15,934)
Depreciation and amortization	(4,745)	(5,558)	(15,141)	(15,685)
Impairment, restructuring and other charges	0	(4,498)	0	(10,690)
Other income (expense), net	(138)	(647)	(622)	(2,835)
Loss before income taxes	(39,534)	(48,916)	(89,064)	(136,291)
Operating Segments
Segment Reporting Information [Line Items]
Total revenue	64,718	53,376	205,209	209,035
Segment profit (loss)	(12,840)	(20,274)	(6,802)	(50,765)
Operating Segments | Medicare
Segment Reporting Information [Line Items]
Total revenue	55,523	45,137	172,787	181,266
Segment profit (loss)	(17,471)	(22,962)	(25,539)	(63,050)
Operating Segments | Individual, Family and Small Business
Segment Reporting Information [Line Items]
Total revenue	9,195	8,239	32,422	27,769
Segment profit (loss)	4,631	2,688	18,737	12,285
Corporate
Segment Reporting Information [Line Items]
Segment profit (loss)	$ (15,257)	$ (12,795)	$ (48,758)	$ (40,382)

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Long-Lived Assets by Geographical Area (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 32,503	$ 38,296
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	32,254	37,915
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 249	$ 381

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Revenue by Major Customers (Details) - Customer Concentration Risk - Revenue	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Humana
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	31%	17%	28%	18%
UnitedHealthCare
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	22%	27%	22%	22%
Aetna
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	8%	12%	7%	12%
Centene
Revenue, Major Customer [Line Items]
Major customer revenue, percentage	3%	10%	3%	13%

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	Sep. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Future sublease income	$ 14.6
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease term	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease term	6 years

Leases - Operating Lease Costs

Leases - Operating Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating lease expense	$ 1,705	$ 1,905	$ 5,395	$ 5,729
Operating sublease income	(518)	(387)	(1,675)	(472)
Total operating lease cost	$ 1,187	$ 1,518	$ 3,720	$ 5,257

Leases - Supplemental Informati

Leases - Supplemental Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Leases [Abstract]
Cash paid for amounts included in the measurement of operating lease liabilities	$ 6,533	$ 5,878
Non-cash investing activities relating to operating lease right-of-use assets	$ 1,285	$ 0
Weighted-average remaining lease term of operating leases	5 years		5 years 8 months 12 days
Weighted-average discount rate used to recognize operating lease right-of-use-assets	5.70%		5.60%

Leases - Maturities of Lease Li

Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating leases
2023 (remainder)	$ 2,193
2024	8,889
2025	9,094
2026	7,760
2027	6,773
Thereafter	8,201
Total lease payments	42,910
Less imputed interest	(5,870)
Total	37,040
Sublease income, remainder of 2023	400
Sublease income, 2024	2,400
Sublease income, 2025	2,600
Sublease income, 2026	2,700
Sublease income, 2027	2,800
Sublease income, thereafter	$ 3,800

Impairment, Restructuring and_3

Impairment, Restructuring and Other Charges - Impairment, Restructuring and Other Charges (Recoveries) (Details) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring and reorganization charges	$ 0	$ 764,000	$ 6,200,000	$ 0	$ 6,956,000
Asset impairment charges	0	3,734,000		0	3,734,000
Impairment, restructuring and other charges	$ 0	$ 4,498,000		$ 0	$ 10,690,000

Impairment, Restructuring and_4

Impairment, Restructuring and Other Charges - Restructuring and Other Liabilities (Details) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring Reserve [Roll Forward]
Balance at December 31, 2022				$ 366,000
Restructuring and reorganization charges	$ 0	$ 764,000	$ 6,200,000	0	$ 6,956,000
Payments				(366,000)
Balance at September 30, 2023	$ 0			$ 0

Impairment, Restructuring and_5

Impairment, Restructuring and Other Charges - Narrative (Details)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($) employee	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Restructuring and Related Activities [Abstract]
Restructuring and reorganization charges	$ 0	$ 764,000	$ 6,200,000	$ 0	$ 6,956,000
Accrued restructuring charges	$ 0			$ 0		$ 366,000
Positions eliminated | employee			339
Percentage of total workforce			14%
Impairment charges, excluding capitalized computer software		3,400,000			3,400,000
Impairment charge		2,500,000			2,500,000
Tangible asset impairment charges		900,000			900,000
In-process internally developed software Impairment charges		$ 300,000			$ 300,000

Debt (Details)

Debt (Details) - Line of Credit - USD ($)			3 Months Ended			9 Months Ended
	Aug. 16, 2022	Feb. 28, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Secured Debt | Term Loan Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 70,000,000
Unamortized issuance costs		5,100,000
Debt issuance costs			$ 2,700,000			$ 2,700,000
Carrying value			$ 67,300,000			$ 67,300,000
Interest rate			13.18%			13.18%
Interest expense			$ 2,400,000	$ 1,700,000		$ 6,800,000	$ 3,900,000
Annual agreement fee		300,000
Minimum liquidity		$ 25,000,000
Outstanding amount as a percentage of total contract assets - commissions receivables (less than)		50%
Secured Debt | Term Loan Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Basis spread on interest rate	0.50%	0.50%
Secured Debt | Term Loan Credit Agreement | London Interbank Offered Rate
Debt Instrument [Line Items]
Basis spread on interest rate		1%
Interest rate		7.50%
Secured Debt | Term Loan Credit Agreement | Base Rate
Debt Instrument [Line Items]
Interest rate	6.50%	6.50%
Secured Debt | Term Loan Credit Agreement | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on interest rate	1%
Interest rate	7.50%
Revolving Credit Facility | Revolving Credit Facility Agreement
Debt Instrument [Line Items]
Amount terminated					$ 75,000,000
Write-off of debt issuance costs					400,000
Borrowings under line of credit					$ 0

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Benefit (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (39,534)	$ (48,916)	$ (89,064)	$ (136,291)
Benefit from income taxes	$ (2,509)	$ (9,767)	$ (8,660)	$ (26,898)
Effective tax rate	6.30%	20%	9.70%	19.70%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Benefit from income taxes	$ (2,509)	$ (9,767)	$ (8,660)	$ (26,898)
Effective tax rate	6.30%	20%	9.70%	19.70%